In a previous blog post, I took a look at Western blots in papers from the lab of Dr. Hoau-Yan Wang at City University of New York (CUNY), mostly related to Cassava Sciences (Nasdaq: $SAVA), its predecessor Pain Therapeutics INC, and its flagship Alzheimer’s Disease drug candidate Simufilam.
While those papers were mainly about the preclinical Simufilam data, here I will review a conference poster reporting on Phase 2 data obtained by Cassava Sciences.
Continue reading “Cassava Sciences: Of Posters and Spaghetti Plots”